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Abstract
The presence of  Herpes Simplex Virüs-1 (HSV-
1) esophagitis in patients with liver transplantation 
has been reported rarely. Among the reports that are 
accessible in the literature, none could have shown tissue 
positivity for Herpes virus-1 DNA via Polymerase Chain 
Reaction (PCR) in patients with liver transplantation. 
This case is presented as the patient was diagnosed 
with herpes esophagitis based on the histopathological 
findings and HSV-1 DNA positivity (detected by PCR) 
in the biopsy material and was treated with Ganciclovir. 
Due to the specific action of Ganciclovir against CMV 
infections, it is natural that the drug cannot use in the 
treatment of HSV infections. However it is reported 
that ganciclovir has been reduced the incidence of 
symptomatic HSV infections after liver transplantation. 
We report on a patient after liver transplantation with 
HSV-1 esophagitis, who was successfully treated with 
Ganciclovir. We assume that most transplant centers 
according to their protocols use ganciclovir for CMV 
prophylaxis, which may contribute to avoid HSV 
infection. 
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INTRODUCTION 
The presence of Herpes Simplex Virus-1 (HSV-
1) esophagitis in the patients with the solid organ 
transplantation has been reported by some case reports in 
the literature [1-3]. The clinical diagnosis of mucosal HSV 
infection is uncertainty, laboratory diagnosis essential to 
guide therapy. HSV infection is best confirmed by isolation 
of virus or demonstration of HSV DNA in tissue culture 
and histopathological findings[4]. However, among the 
reports that are accessible in the literature, none could have 
shown tissue positivity for HSV-1 Deoxyribonucleic acid 
(DNA) via Polymerase Chain Reaction (PCR) in liver 
transplant recipients. Only one publication in a patient 
after renal transplantation reported about HSV-1 DNA 
presence detected by in situ hybridization[3]. It is known that 
acyclovir is the first line therapy in HSV infection. Due to 
the specific action of Ganciclovir against CMV infections, 
it is natural that the drug is not used in the treatment of HSV 
infections. However it is reported that ganciclovir has been 
reduced the incidence of symptomatic HSV infections after 
liver transplantation from 23.5% to 3.5% [5]. We report on a 
patient after liver transplantation with HSV-1 esophagitis, 
who was successfully treated with Ganciclovir. The HSV-1 
diagnosis was established by HSV-1 PCR from esophagus 
tissue sample.
CASE REPORT 
A 24-year-old female patient applied to the Emergency 
Department of our hospital in August 2011 with 
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complaints of nausea, vomiting, fever, acholic feces 
and darkened urine color. The patient’s history revealed 
that she had undergone left hepatectomy+cyst excision 
(12 cm) + partial right lobe resection+ Roux-en-Y 
high hilar ductojejunostomy in February 2011 due to 
her complaint of a palpable mass located on the right 
side of the abdomen and the preliminary diagnosis of 
hydatid cyst and that she had been using antibiotics due 
to cholangitis attacks, which had been recurring over a 
period of 6 months. The patient was hospitalized in the 
gastroenterology department where anastomotic stenosis 
was detected in her via MRCP (Magnetic Resonance 
Cholangiopancreatography). On September 2011, the 
patient underwent PTC (Percutaneous Transhepatic 
Cholangiography) which revealed severe stenosis in 
bilioenteric anastomosis. An external drainage catheter 
was placed. Repeated attempts by interventional radiology 
failed to pass through the stenotic site. Although 
reanastomosis was considered, no appropriate intrahepatic 
bile duct on PTC could be identified for enteric drainage. 
We also wanted to redo ductojejunostomy but in case 
of non dilated biliary system there would be chance of 
not finding anything to anastomose. What we did, we 
schedule him for conventional hepatobiliary surgery 
but at the same time in case we fail to do appropriate 
anastomosis we prepared his relative for living related 
liver transplant (as liver donor). After we found that it is 
impossible to save her liver because of damaged, fibrotic 
strictured biliary system we pursued and switch to liver 
transplant procedure for her living donor. We tried but 
we couldn’t help her with conventional hepatobiliary 
surgery principles. Living related liver transplantation 
from her brother was decided and performed. Her 
induction immunosuppressive regimen was consisted 
tacrolimus (0.1mg/kg/day BID), myophenolate mofetil 
(750 mg BID) and steroid (1gr methylprednisolone IV 
bolus during reperfusion and tapered down to 15 mg/day 
starting from 100 mg/day on POD day 1). Ceftriaxone 
(2x1gr/day) was used for antibacterial prophylaxis for 3 
days while antiviral and antifungal prophylaxes were not 
used. Due to muscular defense and rebound tenderness 
detected during the physical examination of the patient 
performed on the 2nd postoperative day and the increase 
in the hemorrhagic fluid released from the drainage 
tubes, the patient was reoperated for intraabdominal 
hemorrhage. The bleeding and biliary leakage was 
brought under control. Since the patient complained of 
nausea and vomiting during the follow-up, endoscopy 
was performed and a gastric biopsy sample was collected. 
Since macroscopic investigation revealed exudative ulcers 
in the esophagus, Cytomegalovirus (CMV) antigenemia 
and CMV DNA tests were scheduled and Ganciclovir 
(2x5mg/kg/day) treatment was initiated (Figure 1A). On 
the 7th day of the Ganciclovir treatment, on microscopic 
examination of the  esophageal  biopsy, superficial 
squamous epithelium demonstrating area of ulceration 
and  discohesive squamous epithelial cells, some of 
which were multinucleated and containing prominent 
ground–glass nuclei ( consistent with Cowdry Type B 
intranuclear inclusions) with margination of nuclear 
chromatin was revealed. These findings were found to 
be consistent with HSV esophagitis (Figure 1B). HSV-
1 DNA was determined by PCR from biopsy material. [6] 
CMV antigenemia and CMV DNA tests were negative. 
At that time the patient was already treated for 7 days 
ganciclovir. According to clinical improvement of the 
patient, we did not change our regime. After 14 days of 
ganciclovir treatment a control endoscopy was done. 
All ulcers were regressed significantly (Figure 2). PCR 
for HSV DNA was negative. The patient is still alive in 
a good clinical condition. The follow-up is done by our 
outpatient clinic.
    1A   1B
Figure 1
A. Endoscopic View of Esophagus Showing Multiple 
Ulcers and Erosions (Thin Arrows) Before Treatment. 
1B: Esophagial Mucosa With Area of Ulceration and 
Squamous Cells With Cowdry Type B Intranuclear 
inclusions, 400X, H&E.  
Figure 2
Endoscopic View of Esophagus After Ganciclovir 
Treatment
DISCUSSION 
Patients following liver transplantation are at major 
risk to develop both, bacterial and viral infections. 
HSV esophagitis may result from direct extension of 
oropharyngeal HSV infection into the esophagus or may 
occur by reactivation of HSV and spread of the virus to 
the esophageal mucosa via vagus nerve[4]. Although Anti 
HSV IgM and IgG levels were not checked before the 
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transplantation, the lack of oropharyngeal lesions and the 
occasional detection of herpes labialis lesions before the 
transplantation suggested that HSV reactivation resulted 
from immunosuppression. It has been reported that, in 
the first 2-3 postoperative weeks, HSV-1 may be detected 
in the saliva of patients who undergo kidney, liver and 
bone marrow transplantations[4]. Even if these patients 
are asymptomatic, mucocutaneous lesions may develop. 
Since the patient introduced in the present study was 
asymptomatic, her saliva was not investigated for the 
presence of HSV. The abdominal surgery that the patient 
had undergone due to reasons other than transplantation 
surgery and the reoperation that were performed due to 
intraabdominal hemorrhage might have facilitated vagus 
nerve stimulation.   
 If antiviral prophylaxis is used for patients who 
undergo liver transplantation (in order to prevent 
CMV infection, this prophylaxis is used together 
with ganciclovir or valganciclovir), the lesions can be 
treated without even making the diagnosis of herpes 
esophagitis. Our patient was already empirically treated 
with Ganciclovir for 7 days when we obtained the 
positive histopathological results for HSV. In order of the 
clinical improvement we did not change the treatment. 
The repeated endoscopy 14 days after start of treatment 
was clear and confirmed our proceeding. Although, it 
is known that acyclovir is the first line therapy in HSV, 
our patient was treated with Ganciclovir which was 
initiated for possible CMV infection. Both acyclovir and 
ganciclovir are deoxyquanosine analoque but ganciclovir 
has an additional hydroxymethyl group on the acyclic side 
chain. Both of drugs are also effective in HSV infection. 
Acyclovir is approximately 10 times more potent against 
HSV-1, HSV-2 than against Varicella-zoster virus and it is 
even less active against CMV[7]. But ganciclovir is more 
toxic than acyclovir, it is generally not recommended for 
treatment of HSV-1 infection.  Due to the specific action 
of Ganciclovir against CMV infections, it is natural that 
the drug is used in the treatment of CMV infections. 
However it is reported that ganciclovir has been reduced 
the incidence of symptomatic HSV infections after 
liver transplantation from 23.5% to 3.5%[5]. The review 
of the literature did not reveal any previous case of a 
herpes esophagitis patient treated with ganciclovir. We 
assume that most transplant centers according to their 
protocols use ganciclovir for CMV prophylaxis, which 
may contribute to avoid HSV infection. Subsequently 
it is supposed that there are no reports about HSV 
esophagitis in the literature. Since different transplantation 
centers follow different prophylaxis recommendations, 
an increase in the potential prevalence of some rare 
opportunistic infections occurs and some infections cannot 
be diagnosed. In conclusion, viral infections such as HSV 
esophagitis, may affect immunosuppressed patients like 
liver transplant recipients. This should be encountered 
it in term of nausea, vomiting and dysphagia after liver 
transplantation.
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